Long-term health-related quality of life and walking capacity of lung recipients with and without bronchiolitis obliterans syndrome

被引:32
作者
Gerbase, Margaret W. [1 ]
Soccal, Paola M. [1 ,2 ]
Spiliopoulos, Anastase [2 ]
Nicod, Laurent P. [3 ]
Rochat, Thierry [1 ]
机构
[1] Univ Hosp Geneva, Div Pulm Med, CH-1211 Geneva, Switzerland
[2] Univ Hosp Geneva, Div Clin Thorac Surg, CH-1211 Geneva, Switzerland
[3] Univ Hosp Bern, Div Pulm Med, CH-3010 Bern, Switzerland
关键词
D O I
10.1016/j.healun.2008.04.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Outcome after lung transplantation (LTx) is affected by the onset of bronchiolitis obliterans syndrome (BOS) and lung function decline. Reduced health-related quality of life (HRQL) and physical mobility have been shown in patients. developing BOS, but the impact on the capacity to Walk is unknown. We aimed to compare the long-term HRQL and 6-minute walk test (6MWT) between lung recipients affected or not by BOS Grade >= 2. Methods: Fifty-eight patients were prospectively. followed for 5.6 +/- 2.9 years after LTx. Assessments included the St George's Respiratory Questionnaire (SGRQ) and the 6MWT, which were performed yearly. Moreover, clinical complications were recorded to estimate the proportion of the follow-up. time lived without clinical intercurrences after transplant. Analyses were performed using adjusted linear regression and repeated-measures analysis of variance. Results: BOS was a significant predictor of lower SGRQ scores (p < 0.01) and reduced time free of clinical complications (p = 0.001), but not of 6MWT distance (p = 0.12). At 7 years post-transplant, results were: 69.0 +/- 21.8% vs 86.9 +/- 5.6%, p < 0.05 (SGRQ); 58.5 +/- 21.6% vs 88.7 +/- 11.4%, p < 0.01 (proportion of time lived without clinical complications); and 82.2 +/- 10.9% vs 91.9 +/- 14.2%, p = 0.27 (percent of predicted 6MWT), respectively, for patients with BOS and without BOS. Conclusions: Despite significantly less time lived without clinical complications and progressive decline of self-reported health status, the capacity to walk of patients affected by BOS remained relatively stable over time. These, findings may indicate that the development of moderate to severe BOS does not prevent lung recipients from walking independently and pursuing an autonomous life.
引用
收藏
页码:898 / 904
页数:7
相关论文
共 40 条
[1]   Assessment of quality of life in lung transplantation using a simple generic tool [J].
Anyanwu, AC ;
McGuire, A ;
Rogers, CA ;
Murday, AJ .
THORAX, 2001, 56 (03) :218-222
[2]   THE MARKOV PROCESS IN MEDICAL PROGNOSIS [J].
BECK, JR ;
PAUKER, SG .
MEDICAL DECISION MAKING, 1983, 3 (04) :419-458
[3]   Long-term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome [J].
Burton, Christopher M. ;
Carlsen, Jorn ;
Mortensen, Jann ;
Andersen, Claus B. ;
Milman, Nils ;
Iversen, Martin .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2007, 26 (07) :681-686
[4]   Predictors of quality of life and adjustment after lung transplantation [J].
Cohen, L ;
Littlefield, C ;
Kelly, P ;
Maurer, J ;
Abbey, S .
CHEST, 1998, 113 (03) :633-644
[5]  
COOPER JD, 1993, J HEART LUNG TRANSPL, V12, P713
[6]   Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation [J].
Crisafulli, E. ;
Costi, S. ;
Luppi, F. ;
Cirelli, G. ;
Cilione, C. ;
Coletti, O. ;
Fabbri, L. M. ;
Clini, E. M. .
THORAX, 2008, 63 (06) :487-492
[7]   Reference equations for the six-minute walk in healthy adults [J].
Enright, PL ;
Sherrill, DL .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 158 (05) :1384-1387
[8]   Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria [J].
Estenne, M ;
Maurer, JR ;
Boehler, A ;
Egan, JJ ;
Frost, A ;
Hertz, M ;
Mallory, GB ;
Snell, GI ;
Yousem, S .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2002, 21 (03) :297-310
[9]   The sky is the limit: Exercise capacity 10 years post-heart-lung transplantation [J].
Fink, G ;
Lebzelter, J ;
Blau, C ;
Klainman, E ;
Aravot, D ;
Kramer, MR .
TRANSPLANTATION PROCEEDINGS, 2000, 32 (04) :733-734
[10]   Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation [J].
Gerbase, MW ;
Dubois, D ;
Rothmeier, C ;
Spiliopoulos, A ;
Wunderli, W ;
Nicod, LP .
CHEST, 1999, 116 (05) :1265-1272